The significant role of MDM2 in AR degradation has led to the emergence of MDM2-dependent peptide-based proteolysis-targeting chimera (PROTAC) drugs that show efficacy especially in AR-V7 positive PCa [61]. This evidence concerns the gene MDM2 and posterior cortical atrophy.